# US 2014/0193445 A1 · Truncated Secretory Aspartyl Proteinase 2 > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193445 A1 - Document ID: US20140193445A1 - Status: Published application - Kind: A1 - Application number: 14/219,163 - Filed: 2014-03-19 - Published: 2014-07-10 - Earliest claimed: 2007-09-19 - Assignees: Istituto Superiore di Sanita; Pevion Biotech Ltd. - Applicants: Istituto Superiore Di Sanita; Pevion Biotech Ltd. - Inventors: Rinaldo Zurbriggen; Flavia De Bernardis; Antonio Cassone; Silvia Rasi - Web page: https://patentgrep.com/patent/US20140193445A1 ## CPC - A61K 39/0002: {Fungal antigens, e.g. Trichophyton, Aspergillus, Candida} - A61P 31/10: Antimycotics - C12N 9/6478: {Aspartic endopeptidases (3.4.23)} - C12Q 1/68: involving nucleic acids - G01N 33/573: for enzymes or isoenzymes - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a composition comprising an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. ## Claims ### Claim 1 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:1; and, (b) a fragment of the amino acid sequence of SEQ ID NO:1, wherein the fragment is at least 15 amino acids in length, and wherein the fragment is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1; wherein the isolated polypeptide does not have the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7. ### Claim 2 (depends on 1) The isolated polypeptide of claim 1 having the amino acid sequence of SEQ ID NO:1. ### Claim 3 An isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of: (a) the nucleic acid sequence of SEQ ID NO:2; (b) a nucleic acid sequence which is complementary to the nucleic acid sequence of SEQ ID NO:2; (c) a nucleic acid sequence which encodes the amino acid sequence of SEQ ID NO:1; and, (d) a fragment of the nucleic acid sequence of SEQ ID NO:2, wherein the fragment is at least 45 nucleotides in length, and wherein the fragment encodes a polypeptide that is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1; wherein the isolated polynucleotide does not have the nucleic acid sequence of SEQ ID NO:4 or SEQ ID NO:8. ### Claim 4 (depends on 3) The isolated polynucleotide of claim 3 having the nucleic acid sequence of SEQ ID NO:2. ### Claim 5 (depends on 3) A vector comprising the isolated polynucleotide of claim 3. ### Claim 6 (depends on 5) A host cell comprising the vector of claim 5. ### Claim 7 (depends on 1) A composition comprising at least one isolated polypeptide of claim 1. ### Claim 8 (depends on 3) A composition comprising at least one isolated polynucleotide of claim 3. ### Claim 9 A vaccine composition comprising at least one compound selected from the group consisting of: an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:1; and, (b) a fragment of the amino acid sequence of shown in SEQ ID NO:1, wherein the fragment is at least 15 amino acids in length, and wherein the fragment is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1; wherein the isolated polypeptide does not have the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7, and an isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of (a) the nucleic acid sequence of SEQ ID NO:2; (b) a nucleic acid sequence which is complementary to the nucleic acid sequence of SEQ ID NO:2; (c) a nucleic acid sequence which encodes the amino acid sequence of SEQ ID NO:1; and, (d) a fragment of the nucleic acid sequence of SEQ ID NO:2, wherein the fragment is at least 45 nucleotides in length, and wherein the fragment encodes a polypeptide that is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1; wherein the isolated polynucleotide does not have the nucleic acid sequence shown in SEQ ID NO:4 or SEQ ID NO:8. ### Claim 10 (depends on 9) The vaccine composition of claim 9, further comprising one or more additional components selected from the group consisting of excipients, diluents, adjuvants, and delivery vehicles. ### Claim 11 (depends on 1) A method of eliciting an immune response in a mammal, wherein the method comprises administering to the mammal a composition comprising the isolated polypeptide of claim 1. ### Claim 12 (depends on 1) A method of treating a disease in a mammal, wherein the method comprises administering to the mammal a vaccine composition comprising the isolated polypeptide of claim 1. ### Claim 13 A method of treating or preventing Candida infection in a mammal in need thereof, the method comprising administering to the mammal a pharmaceutical composition comprising at least one compound selected from the group consisting of: an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:1; and, (b) a fragment of the amino acid sequence of shown in SEQ ID NO:1, wherein the fragment is at least 15 amino acids in length, and wherein the fragment is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1; wherein the isolated polypeptide does not have the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7, and an isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of (a) the nucleic acid sequence of SEQ ID NO:2; (b) a nucleic acid sequence which is complementary to the nucleic acid sequence of SEQ ID NO:2; (c) a nucleic acid sequence which encodes the amino acid sequence of SEQ ID NO:1, and, (d) a fragment of the nucleic acid sequence of SEQ ID NO:2, wherein the fragment is at least 45 nucleotides in length, and wherein the fragment encodes a polypeptide that is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1; wherein the isolated polynucleotide does not have the nucleic acid sequence shown in SEQ ID NO:4 or SEQ ID NO:8. ### Claim 14 (depends on 12) The method of claim 12, wherein the Candida infection is a Candida albicans infection. ### Claim 15 (depends on 11) The method of claim 11, the composition further comprising one or more additional components selected from the group consisting of excipients, diluents, adjuvants, and delivery vehicles. ### Claim 16 (depends on 15) The method of claim 15, wherein the delivery vehicle is a virosome. ### Claim 17 (depends on 15) The method of claim 15, wherein the isolated polypeptide is linked to the surface of the virosome. ### Claim 18 (depends on 15) The method of claim 15, wherein the isolated polypeptide is contained in the lumen of the virosome. ### Claim 19 (depends on 15) The method of claim 15, wherein the isolated polypeptide is both linked to the surface of and contained in the lumen of the virosome. ### Claim 20 (depends on 13) The method of claim 13, wherein the infection is selected from the group consisting of mucosal, systemic, and any combinations thereof. ### Claim 21 (depends on 20) The method of claim 20, wherein the infection is mucosal and the disease caused by the infection is selected from the group consisting of vulvovaginal and esophageal candidiasis. ### Claim 22 A kit comprising at least one compound selected from the group consisting of: an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:1; and (b) a fragment of the amino acid sequence of shown in SEQ ID NO:1, wherein the fragment is at least 15 amino acids in length, and wherein the fragment is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1; wherein the isolated polypeptide does not have the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7, and an isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of (a) the nucleic acid sequence of SEQ ID NO:2; (b) a nucleic acid sequence which is complementary to the nucleic acid sequence of SEQ ID NO:2; (c) a nucleic acid sequence which encodes the amino acid sequence of SEQ ID NO:1; and, (d) a fragment of the nucleic acid sequence of SEQ ID NO:2, wherein the fragment is at least 45 nucleotides in length, and wherein the fragment encodes a polypeptide that is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1; wherein the isolated polynucleotide does not have the nucleic acid sequence shown in SEQ ID NO:4 or SEQ ID NO:8. ### Claim 23 A method of performing an in vitro diagnosis of a Candida infection in a mammal using a kit, the method comprising contacting a biological sample from the mammal with a reagent from the kit, wherein the kit comprises at least one compound selected from the group consisting of: an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:1; and, (b) a fragment of the amino acid sequence of shown in SEQ ID NO:1, wherein the fragment is at least 15 amino acids in length, and wherein the fragment is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1; wherein the isolated polypeptide does not have the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7, and an isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of (a) the nucleic acid sequence of SEQ ID NO:2; (b) a nucleic acid sequence which is complementary to the nucleic acid sequence of SEQ ID NO:2; (c) a nucleic acid sequence which encodes the amino acid sequence of SEQ ID NO:1; and, (d) a fragment of the nucleic acid sequence of SEQ ID NO:2, wherein the fragment is at least 45 nucleotides in length, and wherein the fragment encodes a polypeptide that is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1; wherein the isolated polynucleotide does not have the nucleic acid sequence shown in SEQ ID NO:4 or SEQ ID NO:8. ### Claim 24 (depends on 22) The kit of claim 22 wherein the Candida infection is a Candida albicans infection. ### Claim 25 (depends on 22) The kit of claim 22, further comprising a reagent for detecting at least one complex that includes the polypeptide.